Immunodetection of DAT is vital in dopamine-related research areas such as Parkinson’s disease (PD), schizophrenia, substance use disorder, attention-deficit-hyperactivity disorder (ADHD), depression, and other neuropsychiatric conditions. Here, SLC6A3 is linked to depressive symptom measurement.